No abstract

Purpose/Objective(s): Trastuzumab (H) improves disease-free and overall survival in HER2+ breast cancer (BC) when added to adjuvant chemotherapy. We describe the impact of H on locoregional failure rates (LFRs). Materials/Methods: 3505 patients (pts) with HER2+ BC were randomized. This analysis included 2763 eligible pts who had lumpectomy (L) or mastectomy (M) with radiotherapy (RT) or M without RT in this 3-arm phase 3 trial of adjuvant doxorubicin (A), cyclophosphamide (C), paclitaxel (T)

No abstract

No abstract

No abstract